Michigan State University

Total Page:16

File Type:pdf, Size:1020Kb

Michigan State University ..____ LIEMRY Michigan State University ———— OVERDUE FINES: 25¢ per day per ite- RETURNING LIBRARY MATERIALS: Place in book return to remove charge from c1 rcuht1on records BRAIN IRON'IN THE RAT: DISTRIBUTION, SEX DIFFERENCES, AND EFFECTS OF SEX HORMONES By Joanna Marie Hill A DISSERTATION Submitted to Michigan State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Department of Zoology 1981 ABSTRACT BRAIN IRON IN THE RAT: DISTRIBUTION, SEX DIFFERENCES, AND EFFECTS OF SEX HORMONES By Joanna Marie Hill Although the brain contains relatively large amounts of iron, and iron deficiency alters behavior, little is known about those factors which affect brain iron or the role of n J .r iron in the brain. Sex hormones are responsible for sex r’ ’7 differences in many aspects of iron metabolism throughout ,l' .3 I the body. 6// The purposes of this study were to: (l) localize iron deposits in the rat brain; (2) determine if a sex difference exists in brain iron stores; (3) determine the effects on brain iron levels of natural events in which sex hormones fluctuate (e.g. estrous cycle and pregnancy); and (4) determine if exogenous estrogen alters the effects of ovari- ectomy and castration on brain iron levels. Brain iron was localized by histochemical methods and direct measurement of iron concentrations of high-iron areas (pooled globus pallidus and substantia nigra) and lower iron areas (cortex) of the brain, as well as the serum and liver were made by spectr0photometry. This study has determined that brain iron: is unevenly distributed in the rat brain; occurs in different cellular and extracellular compartments in different parts of the Joanna Marie Hill brain; and increases with age. Brain iron fluctuates during the estrous cycle, rising to the highest levels during proestrus. During the first third of pregnancy brain iron concentration rises and although the level falls later, pregnancy does not deplete brain iron. There is a sex difference in the brain iron concentration between males and females in the proestrus stage of the estrous cycle, and ovariectomy and castration have different effects on brain iron levels. The results of this study suggest that: the pattern of iron distribution may be related to the participation of iron in the metabolism of peptides; brain iron accumulation is influenced by ovarian hormones; and iron plays a role in neuroendocrine regulation. ACKNOWLEDGEMENTS Grateful acknowledgment is made to my coadvisers Dr. J.I. Johnson and Dr. R.C. Switzer for their interest, guidance and constructive criticisms throughout all stages of this study. Also, the helpful comments of my committee members Dr. M. Balaban, Dr. C.D. Tweedle and Dr. S.T. Kitai are sincerely appreciated. It is a pleasure to acknowledge Dr. P.D. MacLean, Chief, Laboratory of Brain Evolution and Behavior, NIMH not only for his enthusiasitc support but also for the laboratory space, equipment and supplies he made available to me. I wish to thank Mrs. J. Bupp for her editorial com- ments and competent typing of the dissertation and Mr. R. Harbaugh for invaluable technical assistance with surgical procedures and the care and breeding of animals. I thank also my husband, Jim for his assistance with the statistical analysis and for the patience, understand- ing and support I received from him and my daughters, Andrea and Katherine, without which this study would not have been possible. ii TABLE OF CONTENTS PAGE LIST OF TABLES ........................................ iv LIST OF FIGURES ........................................ v INTRODUCTION ........................................... 1 LITERATURE REVIEW ...................................... 4 MATERIALS AND METHODS ................................. 37 HISTOCHEMISTRY ...................................... 37 Animals ............................................ 37 Treatment Groups ................................... 37 Preparation of Tissue .............................. 40 Staining techniques ................................ 43 Analysis of Data ........... , ....................... 49 SPECTROPHOTOMETRY ................................... 50 Animals ............................................ 50 Treatment Groups ................................... 50 Collection of tissue for the Spectrophotometric Measurement of Iron ................................ 59 Requirements for the Spectrophotometric Measurement of Iron ................................ 61 Solutions for Iron Spectrophotometry ............... 63 Determination of Serum Iron ........................ 65 Preparation of Liver Extract ....................... 66 Determination of Liver Iron ........................ '68 Preparation of Brain Extract ....................... 69 Determination of Brain Iron ........................ 72 Analysis of Data ................................... 74 RESULTS ............................................... 75 HISTOCHEMISTRY ...................................... 75 SPECTROPHOTOMETRY .................................. 108 DISCUSSION ........................................... 134 SUMMARY .............................................. ‘157 BIBLIOGRAPHY ........................................ 160 iii LIST OF TABLES TABLE PAGE The Distribution of Non-haemin Iron in Different Parts of the Human Brain Autopsy Cases, 30-100 Years of Age ....................... 17 Determination of Iron in the Subcellular Fractions of Different Brain Areas ............... 27 Summary of Iron Measurement Study ................ 58 Analysis of Variance and Tukey's Test of Iron Measures of Estrous Cycle and Sex Difference Data ............................................ 111 Analysis of Variance with Regression of Iron Measures of Pregnancy Data ...................... 116 Analysis of Variance with Orthogonal Contrasts of Iron Measures of Control Males (CM), Cast- rated Males (CAST), Castrated Males with Estrogen Implants (CAST+EST), Intact Females in Estrus (ESTF), Ovariectomized Females (OVX) and Ovariectomized Females with Estrogen Implants (0VX+EST) .............................. 122 The Distribution of Monoamines and GABA in Iron Concentrating Areas of the Rat Brain ............ 136 The Distribution of Peptides and Iron Concent- rating Areas of the Rat Brain ................... 139 iv LIST OF FIGURES FIGURE PAGE 1. Distribution of iron. Perl's-DAB stain for iron, no counterstain. Stained areas are accumulations of iron. Parasagittal view of a 52 week old female rat. Magnification X 4.5 ........................................ ..76 Distribution of iron in the forebrain at the level of the anterior commissure in a 32 week old female rat. Perl's-DAB, no counterstain. Stained areas are accumul- ations of iron. Magnification X 5.4 ......... .78 Distribution of iron in the forebrain at the level of the anterior commissure in a 32 week old male rat. Perl's-DAB, no counterstain. Stained areas are accumula— tions of iron. Magnification X 5.4 .......... ..78 Distribution of iron in the forebrain at the level of the globus pallidus in a 32 week old female rat. Perl's—DAB, no counter- stain. Stained areas are accumulations of iron. Magnification X 5.4 ................... ..78 Distribution of iron in the forebrain at the level of the globus pallidus in a 32 week old male rat. Perl's-DAB, no counterstain. Stained areas are accumulations of iron. Magnification X 5.4 .......................... ..78 Distribution of iron in the forebrain at the level of the thalamus in a 32 week old female rat. Perl's-DAB, no counterstain. Stained areas are accumulations of iron. Magnification X 5.4 .......................... ..80 Distribution of iron in the midbrain at the level of the substantia nigra in a 32 week old female rat. Perl's-DAB, no counterstain. Stained areas are accumulations of iron. Magnification X 5.4 .......................... ..80 V LIST OF FIGURES -— continued FIGURE PAGE Distribution of iron in the midbrain at the level of the substantia nigra in a 32 week old male rat. Perl's-DAB, no counterstain. Stained areas are accumulations of iron. Magnification X 5.4 ............................. 80. Photomicrograph of iron accumulation in area postrema and dorsal to the central canal Darker staining areas are accumulations of iron. Perl's-DAB counterstained with thionin. Magnification X 100 ............................. 83 10. Photomicrograph of iron accumulation in the subfornical organ and choroid plexus. Darker staining areas are accumulations of iron. Perl's-DAB counterstained with thionin. Magnification X 100 ............................. 83 ll. Photomicrograph of iron-filled fibers in the lateral edge of the optic tract. Iron = brown. Perl's-DAB counterstained with thionin. Magnification X 200 ............................. 86 12. Dark-field photomicrograph of iron—filled tanycytes and clumps of granules in the ventro-medial hypothalamus. Iron = white. Perl's-DAB counterstained with thionin. Magnification X 120 ............................. 86 13. Dark-field photomicrograph of iron-filled structures in the ventro-medial hypothalamus and arcuate area. Iron = white. Perl's-DAB counterstained with thionin. Magnification X 120 ........................................... 88 14. Dark-field photomicrograph of iron—filled structures in the ventro-medial hypothalamus and median eminence. Iron = white. Perl's-DAB counterstained with thionin. Magnification X 120 ........................................... 88 vi LIST OF FIGURES -- continued FIGURE PAGE 15. Photomicrograph of iron distribution in the ventral pallidum, islands
Recommended publications
  • Mice Carrying a Human GLUD2 Gene Recapitulate Aspects of Human Transcriptome and Metabolome Development
    Mice carrying a human GLUD2 gene recapitulate aspects of human transcriptome and metabolome development Qian Lia,b,1, Song Guoa,1, Xi Jianga, Jaroslaw Brykc,2, Ronald Naumannd, Wolfgang Enardc,3, Masaru Tomitae, Masahiro Sugimotoe, Philipp Khaitovicha,c,f,4, and Svante Pääboc,4 aChinese Academy of Sciences Key Laboratory of Computational Biology, Chinese Academy of Sciences-Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031 Shanghai, China; bUniversity of Chinese Academy of Sciences, 100049 Beijing, China; cMax Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany; dMax Planck Institute of Molecular Cell Biology and Genetics, D-01307 Dresden, Germany; eInstitute for Advanced Biosciences, Keio University, 997-0035 Tsuruoka, Yamagata, Japan; and fSkolkovo Institute for Science and Technology, 143025 Skolkovo, Russia Edited by Joshua M. Akey, University of Washington, Seattle, WA, and accepted by the Editorial Board April 1, 2016 (received for review September 28, 2015) Whereas all mammals have one glutamate dehydrogenase gene metabolic flux from glucose and glutamine to lipids by way of the (GLUD1), humans and apes carry an additional gene (GLUD2), TCA cycle (12). which encodes an enzyme with distinct biochemical properties. To investigate the physiological role the GLUD2 gene may We inserted a bacterial artificial chromosome containing the human play in human and ape brains, we generated mice transgenic for GLUD2. GLUD2 gene into mice and analyzed the resulting changes in the a genomic region containing human We compared effects transcriptome and metabolome during postnatal brain development. on gene expression and metabolism during postnatal development Effects were most pronounced early postnatally, and predominantly of the frontal cortex of the brain in these mice and their wild-type genes involved in neuronal development were affected.
    [Show full text]
  • O O2 Enzymes Available from Sigma Enzymes Available from Sigma
    COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc.
    [Show full text]
  • Natural Product Biosyntheses in Cyanobacteria: a Treasure Trove of Unique Enzymes
    Natural product biosyntheses in cyanobacteria: A treasure trove of unique enzymes Jan-Christoph Kehr, Douglas Gatte Picchi and Elke Dittmann* Review Open Access Address: Beilstein J. Org. Chem. 2011, 7, 1622–1635. University of Potsdam, Institute for Biochemistry and Biology, doi:10.3762/bjoc.7.191 Karl-Liebknecht-Str. 24/25, 14476 Potsdam-Golm, Germany Received: 22 July 2011 Email: Accepted: 19 September 2011 Jan-Christoph Kehr - [email protected]; Douglas Gatte Picchi - Published: 05 December 2011 [email protected]; Elke Dittmann* - [email protected] This article is part of the Thematic Series "Biosynthesis and function of * Corresponding author secondary metabolites". Keywords: Guest Editor: J. S. Dickschat cyanobacteria; natural products; NRPS; PKS; ribosomal peptides © 2011 Kehr et al; licensee Beilstein-Institut. License and terms: see end of document. Abstract Cyanobacteria are prolific producers of natural products. Investigations into the biochemistry responsible for the formation of these compounds have revealed fascinating mechanisms that are not, or only rarely, found in other microorganisms. In this article, we survey the biosynthetic pathways of cyanobacteria isolated from freshwater, marine and terrestrial habitats. We especially empha- size modular nonribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) pathways and highlight the unique enzyme mechanisms that were elucidated or can be anticipated for the individual products. We further include ribosomal natural products and UV-absorbing pigments from cyanobacteria. Mechanistic insights obtained from the biochemical studies of cyanobacterial pathways can inspire the development of concepts for the design of bioactive compounds by synthetic-biology approaches in the future. Introduction The role of cyanobacteria in natural product research Cyanobacteria flourish in diverse ecosystems and play an enor- [2] (Figure 1).
    [Show full text]
  • Production of Monatin and Monatin Precursors Herstellung Von Monatin Und Monatinvorläufer Production De Monatine Et Précurseurs De Monatine
    (19) TZZ ¥Z Z_T (11) EP 2 302 067 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12P 13/04 (2006.01) C12N 9/88 (2006.01) 05.03.2014 Bulletin 2014/10 C12N 9/10 (2006.01) C12N 1/21 (2006.01) (21) Application number: 10009952.2 (22) Date of filing: 21.10.2004 (54) Production of monatin and monatin precursors Herstellung von Monatin und Monatinvorläufer Production de monatine et précurseurs de monatine (84) Designated Contracting States: • Sanchez-Riera, Fernando A. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Eden Prairie, MN 55346 (US) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • Cameron, Douglas C. Plymouth, MN 55447 (US) (30) Priority: 21.10.2003 US 513406 P • Desouza, Mervyn L. Plymouth, MN 55441 (US) (43) Date of publication of application: • Rosazza, Jack 30.03.2011 Bulletin 2011/13 Iowa City, IA 55240 (US) • Gort, Steven J. (62) Document number(s) of the earlier application(s) in Brooklyn Center, MN 55429 (US) accordance with Art. 76 EPC: • Abraham, Timothy W. 04795689.1 / 1 678 313 Minnetonka, MN 55345 (US) (73) Proprietor: Cargill, Incorporated (74) Representative: Wibbelmann, Jobst Wayzata, MN 55391-5624 (US) Wuesthoff & Wuesthoff Patent- und Rechtsanwälte (72) Inventors: Schweigerstrasse 2 • McFarlan, Sara C. 81541 München (DE) St.Paul, MN 55116 (US) • Hicks, Paula M. (56) References cited: Bend, Oregon 97702 (US) WO-A-03/056026 WO-A-2005/016022 • Zidwick, Mary Jo WO-A-2005/020721 WO-A2-03/091396 Wayzata, MN 55391 (US) WO-A2-2005/014839 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • WO 2017/123676 A9 20 July 2017 (20.07.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/123676 A9 20 July 2017 (20.07.2017) P O P C T (51) International Patent Classification: 16 November 2016 (16. 11.2016) US C12N 9/78 (2006.0 1) C12N 1/00 (2006.0 1) 15/379,445 14 December 20 16 ( 14. 12.20 16) us A61K 35/74 (2015.01) C12N 15/52 (2006.01) 62/434,406 14 December 2016 (14. 12.2016) us A61K 35/741 (2015.01) C12N 15/74 (2006.01) 62/439,820 28 December 2016 (28. 12.2016) us C07K 14/195 (2006.01) 62/439,871 28 December 2016 (28. 12.2016) us PCT/US201 6/069052 (21) International Application Number: 28 December 2016 (28. 12.2016) us PCT/US20 17/0 13074 62/443,639 6 January 2017 (06.01.2017) us (22) International Filing Date: PCT/US201 7/013072 11 January 2017 ( 11.01 .2017) 11 January 2017 ( 11.01 .2017) us (25) Filing Language: English Applicant: SYNLOGIC, INC. [US/US]; 130 Brookline Street, #201, Cambridge, MA 02139 (US). (26) Publication Language: English (72) Inventors: FALB, Dean; 180 Lake Street, Sherborn, MA (30) Priority Data: 01770 (US). KOTULA, Jonathan, W.; 345 Washington 62/277,413 11 January 2016 ( 11.01.2016) US Street, Somerville, MA 02143 (US). ISABELLA, Vin¬ 62/277,450 11 January 2016 ( 11.01.2016) us cent, M.; 465 Putnam Avenue, Unit 1, Cambridge, MA 62/277,455 11 January 2016 ( 11.01.2016) us 02139 (US).
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Open Full Article
    BIOLOGIA PLANTARUM (PRAHA) 33 (5):395-407, 1991 Proposed Enzymes of Auxin Biosynthesis and Their Regulation II. Tryptophan Dehydrogenase Activity in Plants. M. KUT/~t~EK and SULTANA TERZIIVANOVA-DIMOVA* Institute of Experimental Botany, Czechoslovak Academy of Sciences, Ke dvoru 15, 166 30 Praha 6, Czechoslovakia *Institute of Plant Physiology "M. Popov", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria Abstract. In pea, maize and tomato plants a hitherto undescribed L-tryptophan dehydrogenase activity (TDH) has been detected. This enzyme catalyzes the reversible formation of indolepyruvic acid (IPyA) from L-tryptophan (L-trp). TDH and L-glutamate dehydrogenase (GDH), related enzymes in their mode of action, could be separated by gel chromatography. Enzymatic activity of TDH was sustained by both pyridine coenzymes NAD/NADP. With pea TDH the coenzyme NAD displays, at optimum pH 8.5 and at room temperature, only about 40-70 % of the activity of NADP. The amination of IPyA is catalysed more actively than the deamination of L-trp. L-trp/IPyA, L-glu/ketoglutarate, L-ala/pyruvate reacted as dehydrogenase substrates; L-phe/phenylpyruvate, D-trp and D-phe did not react with pea enzyme extracts. A considerable similarity between the active centres of TDH and GDH has been found using inhibitors: absence of heavy metals, presence of a carbonyl group, indispensibility of bivalent ions for the enzyme activity. Pea TDH and GDH were distinctly inhibited by sodium azide. For the activity of TDH the presence of SH groups is less important than for GDH. The TDH activity in the investigated plants was lower than the GDH activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0112260 A1 Abraham Et Al
    US 2005O112260A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0112260 A1 Abraham et al. (43) Pub. Date: May 26, 2005 (54) MONATIN TABLETOPSWEETENER (21) Appl. No.: 10/903,582 COMPOSITIONS AND METHODS OF MAKING SAME (22) Filed: Aug. 2, 2004 (75) Inventors: Timothy W. Abraham, Minnetonka, Related U.S. Application Data MN (US); Douglas C. Cameron, Plymouth, MN (US); Melanie J. (60) Provisional application No. 60/492,014, filed on Aug. Goulson, Dayton, MN (US); Paula M. 1, 2003. Hicks, Eden Prairie, MN (US); Michael O O G. Lindley, Crowthorne (GB); Sara C. Publication Classification McFarlan, St.Paul, MN (US); James 7 R. Millis, Plymouth, MN (US); John s - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A: Rosazza, Iowa City, IA (US); Lishan ( 2) O O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - /5 Zhao, Carlsbad, CA (US); David P. Weiner, Del Mar, CA (US) (57) ABSTRACT Correspondence Address: The present invention relates to novel Sweetener composi CARGILL, INCORPORATED tions comprising monatin and methods for making Such LAW/24 compositions. The present invention also relates to Sweet 15407 MCGINTY ROAD WEST ener compositions comprising Specific monatin Stereoiso WAYZATA, MN 55391 (US) mers, Specific blends of monatin Stereoisomers, and/or monatin produced via a biosynthetic pathway in Vivo (e.g., (73) Assignee: Cargill, Inc. inside cells) or in vitro. -- re Tryptophan Indole-3-lactic
    [Show full text]
  • Crystal Structure of L-Tryptophan Dehydrogenase
    Photon Factory Activity Report 2018 #36 (2019) AR-NE3A/2017G010 Crystal structure of L-tryptophan dehydrogenase Taisuke Wakamatsu 1, *, Haruhiko Sakuraba 2, *, Megumi Kitamura 1, Yuichi Hakumai1, Kenji Fukui 3, Kouhei Ohnishi 4, Makoto Ashiuchi 1, and Toshihisa Ohshima 5 1 Agricultural Science, Graduate School of Integrated Arts and Sciences, Kochi University, Kochi, Japan 2 Department of Applied Biological Science, Faculty of Agriculture, Kagawa University, Kagawa, Japan 3 Department of Biochemistry, Osaka Medical College, Osaka, Japan 4 Research Institute of Molecular Genetics, Kochi University, Kochi, Japan 5 Department of Biomedical Engineering, Osaka Institute of Technology, Osaka, Japan 1 Introduction preferred substrate, whereas phenylpyruvate, the 2-oxo NAD(P)-dependent L-amino acid dehydrogenases (EC analog of L-Phe, was inert as a substrate. Despite these 1.4.1.x) catalyze reversible oxidative deamination of L- interesting observations, there exists no structural amino acids to their corresponding 2-oxo acids and information on TrpDH. Thus, we employed X-ray ammonia in the presence of NAD(P). So far, more than crystallography to solve the apo-structure of NpTrpDH, fifteen types of L-amino acid dehydrogenases have been identified from various organisms and characterized 2 Experiment extensively. In particular, detailed structure and function Data were collected under cryo conditions at the analyses of L-Glu/L-Leu/L-Phe dehydrogenases have led to Beamline AR-NE3A at Photon Factory in Japan. The the elucidation of their catalytic mechanisms. crystal structure of LeuDH from Sporosarcina Consequently, several L-amino acid dehydrogenases have psychrophila (SpLeuDH, PDB ID: 3VPX, amino acid been successfully used for the syntheses for chiral amino sequence identity: 49%) was applied as a search model, acids and their analogs, for developing biosensors for L- and the program PHENIX was used for molecular amino acids.
    [Show full text]
  • Targeting Glutamine Addiction in Gliomas
    cancers Review Targeting Glutamine Addiction in Gliomas Marta Obara-Michlewska and Monika Szeliga * Department of Neurotoxicology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawi´nskiegoStreet, 02-106 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-22-608-6416 Received: 20 December 2019; Accepted: 27 January 2020; Published: 29 January 2020 Abstract: The most common malignant brain tumors are those of astrocytic origin, gliomas, with the most aggressive glioblastoma (WHO grade IV) among them. Despite efforts, medicine has not made progress in terms of the prognosis and life expectancy of glioma patients. Behind the malignant phenotype of gliomas lies multiple genetic mutations leading to reprogramming of their metabolism, which gives those highly proliferating cells an advantage over healthy ones. The so-called glutamine addiction is a metabolic adaptation that supplements oxidative glycolysis in order to secure neoplastic cells with nutrients and energy in unfavorable conditions of hypoxia. The present review aims at presenting the research and clinical attempts targeting the different metabolic pathways involved in glutamine metabolism in gliomas. A brief description of the biochemistry of glutamine transport, synthesis, and glutaminolysis, etc. will forego a detailed comparison of the therapeutic strategies undertaken to inhibit glutamine utilization by gliomas. Keywords: glioma; glutamine; glutamate; glutaminase; glutamine synthetase; glutamate dehydrogenase; therapy 1. Introduction The metabolism of neoplasms has evolved to meet the demands of their high proliferative activity and growth in adverse conditions of hypoxia, nutrient shortage, and immunological pressure of the host. The reprogrammed metabolism of neoplasms, eventually adapting them to specific growth requirements and conditions, involves addiction to glucose (the Warburg effect, oxidative glycolysis) and/or glutamine.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,435,765 B2 Abraham Et Al
    USOO84357.65B2 (12) United States Patent (10) Patent No.: US 8,435,765 B2 Abraham et al. (45) Date of Patent: *May 7, 2013 (54) POLYPEPTIDES AND BIOSYNTHETIC 5,994,559 A 1 1/1999 Abushanab et al. PATHWAYS FOR THE PRODUCTION OF 3.35 R 3.399 this et al. MONATIN AND ITS PRECURSORS 6,489,1004. W I B1 12/2002 Liaoat Ka et al. 7,064,219 B2 6/2006 Kawahara et al. (75) Inventors: Timothy W. Abraham, Wayzata, MN 7,390,909 B2 6/2008 Kawahara et al. (US); Douglas C. Cameron, Plymouth, 7.534,898 B2 5/2009 Amino et al. MN (US); Paula M. Hicks, Bend, OR 7,572,607 B2 * 8/2009 Hicks et al. ................... 435/121 (US); Sara C. McFarlan, St Paul MN 7,582.455 B2 * 9/2009 Brazean et al. ............... 435/121 s O O s a wo s 7,781,005 B2 8, 2010 Mori (US); James R. Millis, Plymouth, MN 7,888,081 B2 2/2011 Khare et al. (US); John Rosazza, Iowa City, IA 8,003,361 B2 8/2011 Brady et al. (US); David P. Weiner, Del Mar, CA 8,076,107 B2 12/2011 Buddoo et al. (US); Lishan Zhao, Carlsbad, CA (US) 2003/02284.03 A1 12/2003 Amino et al. s s s 2004/0063175 A1 4/2004 Abraham et al. 2005, 0004394 A1 1/2005 Kawahara et al. (73) Assignee: Cargill, Incorporated, Wayzata, MN 2005.0009153 A1 1/2005 Sugiyama et al. (US) 2005/0020508 A1 1/2005 Amino et al. 2005/OO95670 A1 5/2005 Ikeda et al.
    [Show full text]